



May 29, 2026

Press Release

C4U Corporation

C4U Completed the AMED Stage-Gate Evaluation for Stage 2

C4U Corporation ('C4U') is pleased to announce that we have successfully passed the interim (stage-gate) evaluation and have been approved to transition to Stage 2 under 'Strengthening Program for Pharmaceutical Startup Ecosystem' by the Japanese Agency for Medical Research and Development (AMED). [C4U has been selected for this program in 2025.](#)

For further details, please refer to the announcement from AMED (only in Japanese).

https://www.amed.go.jp/program/list/19/02/005_r8_chukan.html

With the support of this program, C4U will accelerate our research and development to demonstrate the safety and efficacy of a hematopoietic stem cell transplantation for primary immunodeficiency utilising CRISPR-Cas3 genome editing technology.

About C4U Corporation

C4U is a privately held biotech company based in Osaka, Japan, and is focused on the development of safe and efficient gene therapies utilizing its proprietary next generation CRISPR-Cas3 gene editing platform. In comparison to the CRISPR-Cas9 platform, CRISPR-Cas3 presents the distinct benefits of: 1) no off-target by the higher selectivity of deletion site (improved safety); 2) efficient knockouts by the larger deletion of gene sequences; and 3) an entirely independent patent portfolio. C4U has been granted a worldwide exclusive license to CRISPR-Cas3 by Osaka University for use in eukaryotic cells thus simplifying sublicensing transactions which is in sharp contrast to the complex and heavily litigated CRISPR-Cas9 patent landscape.

<https://www.crispr4u.jp/en/>

Contact Information

Address : Yamadaoka 2-8, Suita, Osaka 565-0871, Japan

E-mail : info@crispr4u.com